The Global Multiple Myeloma Treatment Market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%.
The company's latest report* states that this increase, which will occur across the eight major markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada, will be driven primarily by rising multiple myeloma prevalence as a result of an aging population.
Additionally, approvals during the forecast period for drugs that will supplement current market leaders, such as Revlimid, and offer improved therapeutic options, mainly in the relapsed/refractory setting, will also boost the market. Promising examples include ixazomib, ARRY-520 (filanesib), elotuzumab and daratumumab.
Get Sample Brochure of report for TOC & Key Market Insights @ http://www.marketintelreports.com/pdfdownload.php?id=gbihc365mr
Although multiple myeloma remains incurable, greater understanding of its underlying cellular and molecular biology has driven novel therapy development, with clinical outcomes improving significantly as a result.
"While some late-stage pipeline drugs will have a low impact, others have demonstrated promising clinical results in specific patient populations, including elotuzumab and daratumumab. These products are therefore likely to provide physicians with increased choice and complexity in multiple myeloma treatment over the forecast period."
However, the analyst adds that various market barriers, such as a limited target patient population, will restrict any further growth in the multiple myeloma therapeutics arena by 2021.
Multiple myeloma's rarity and designation as an orphan disease limits the available treatment population, in turn hindering the potential revenues that can be generated from this indication. This, combined with high drug development costs, can deter manufacturers from investing in this area.
On the other hand, incentives for orphan disease drug development, along with the ability to reposition drugs from one indication to another, could help to counter these challenges and drive further research into multiple myeloma treatment.
The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.
Key Benefits of Report:
Browse more details @ http://www.marketintelreports.com/report/gbihc365mr/multiple-myeloma-therapeutics-in-major-developed-markets-to-2021--growth-driven-by-rising-prevalence-continued-success-of-revlimid-and-emerging-supplementary-treatments
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.